Open AccessRecombinant CRAMP-producing Lactococcus lactis attenuates dextran sulfate sodium-induced colitis by colonic colonization and inhibiting p38/NF-κB signaling
Author(s) -
Jiahong Li,
Shiwen Yu,
Xiaohua Pan,
Ming Zhang,
Zhuwu Lv,
Li-Long Pan,
Jia Sun
Publication year - 2021
Publication title -
food and nutrition research/food and nutrition research. supplement
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 37
eISSN - 1654-6628
pISSN - 1654-661X
DOI - 10.29219/fnr.v65.5570
Subject(s) - lactococcus lactis , colitis , cathelicidin , inflammatory bowel disease , medicine , inflammation , immunology , microbiology and biotechnology , biology , immune system , innate immune system , lactic acid , genetics , disease , bacteria
Inflammatory bowel diseases (IBDs) are generally characterized by persistent abdominal pain and diarrhea caused by chronic inflammation in the intestine. Cathelicidins are antimicrobial peptides with pleiotropic roles in anti-infection, wound healing, and immune modulation. However, the sensitivity to the acidic environment and short half-life of cathelicidins limit their application in IBD treatment. Recombinant cathelicidin-related antimicrobial peptide (CRAMP)-producing Lactococcus lactis may represent a potential approach for IBD therapy.